BCLI - Brainstorm Cell Therapeutics Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

BCLI

BRAINSTORM CELL THERAPEUTICS INC.

OTC

$1.12

▼ DOWN 3.45% (-0.04)

KEY STATISTICS

Market Cap$12.36 M

52w High$1.69

52w Low$0.46

Dividend Yield—

Frequency—

P/E-0.69

Volume1.16K

Shares Out.11.03M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Chaim Lebovits

COMPENSATION 2026

Salary$0

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$750,303

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 7, 2003

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 16, 2026

DayMonday

Rev. Est.—

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2024-10-01	Reverse	1:15
2014-09-16	Reverse	1:15
2003-09-04	Forward	2:1

PRICE

$1.12 ▼ DOWN 3.45% (−$0.04)

OVERLAYS

About Brainstorm Cell Therapeutics Inc.

https://www.brainstorm-cell.com ↗

Brainstorm Cell Therapeutics Inc. develops autologous stem cell therapies, like NurOwn, to treat neurodegenerative diseases such as ALS, multiple sclerosis, and Alzheimer's, with ongoing clinical trials and manufacturing partnerships.

INDUSTRY

Biotechnology

A PRODUCT BRAINSTORM CELL THERAPEUTICS INC. IS KNOWN FOR

NurOwn®

NurOwn® is an autologous cell therapy using a patient's own modified mesenchymal stem cells to secrete neurotrophic factors, aiming to slow or stabilize neurodegenerative diseases like ALS and PMS.